Existing investor Hadasit Bio-Holdings took part in a round that pushed the immuno-oncology therapy developer's overall funding tally to more than $35m.
Israel-based cancer immunotherapy developer Kahr Medical has raised $18m in funding from investors including Hadasit Bio-Holdings, the publicly-listed drug commercialisation arm of healthcare provider Hadassah University Hospital.
The round was led by venture capital firm Flerie Invest and included Mirae Asset Venture Investment, Oriella and Pavilion Capital. It is expected to close next month.
Kahr is developing immuno-oncology drugs intended to spur the body’s immune system into fighting the disease. The capital will enable it to conduct a phase 1/2…
